Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Antibodies Bispecific”

417 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 417 results

Testing effectiveness (Phase 2)Looking for participantsNCT06799611
What this trial is testing

An Open, Exploratory Clinical Study of CM336 in the Treatment of Immune Thrombocytopenia

Who this might be right for
Immune Thrombocytopenia (ITP)Treatment
Institute of Hematology & Blood Diseases Hospital, China 20
Early research (Phase 1)Study completedNCT00911898
What this trial is testing

MM-111 in Patients With Advanced, Refractory Her2 Amplified, Heregulin Positive Cancers

Who this might be right for
Her2 Amplified Solid TumorsMetastatic Breast Cancer
Merrimack Pharmaceuticals 20
Testing effectiveness (Phase 2)Active Not RecruitingNCT05660967
What this trial is testing

Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma

Who this might be right for
Diffuse Large B-Cell Lymphoma
Genmab 111
Testing effectiveness (Phase 2)Study completedNCT01741792
What this trial is testing

Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Who this might be right for
Diffuse Large B-cell Lymphoma
Amgen Research (Munich) GmbH 25
Early research (Phase 1)Looking for participantsNCT07067567
What this trial is testing

AK146D1 for Injection in Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumors
Akeso 200
Early research (Phase 1)Study completedNCT03875209
What this trial is testing

10E8.4/iMab Bispecific Antibody in HIV-uninfected and HIV-infected Adults

Who this might be right for
HIV-1-infection
David Ho 54
Early research (Phase 1)Study completedNCT03922204
What this trial is testing

Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies

Who this might be right for
Advanced CancerSolid Tumor, AdultB-cell Lymphoma, Adult
Merus B.V. 72
Not applicableNot Yet RecruitingNCT06769555
What this trial is testing

BCMA/CD3 BiTE for RRAL or NDAL Amyloidosis With Insufficient Depth of Hematologic Response After Induction Therapy

Who this might be right for
AL Amyloidosis
Institute of Hematology & Blood Diseases Hospital, China 20
Testing effectiveness (Phase 2)Looking for participantsNCT06635785
What this trial is testing

Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumor
OncoC4, Inc. 387
Testing effectiveness (Phase 2)Ended earlyNCT04750239
What this trial is testing

Safety and Clinical Activity of Nivatrotamab in Relapsed/Recurrent Metastatic Small-cell Lung Cancer

Who this might be right for
SCLC
Y-mAbs Therapeutics 3
Early research (Phase 1)Looking for participantsNCT06147037
What this trial is testing

A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours

Who this might be right for
Advanced Solid TumorMetastatic Colorectal CarcinomaHead and Neck Squamous Cell Carcinoma+4 more
AstraZeneca 70
Large-scale testing (Phase 3)Active Not RecruitingNCT05587374
What this trial is testing

Cadonilimab (PD-1/CTLA-4 Bispecific Blockade) and Chemoradiotherapy in Nasopharyngeal Carcinoma (GEMSTONE)

Who this might be right for
Nasopharyngeal CarcinomaNasopharyngeal Cancer
Sun Yat-sen University 490
Very early researchLooking for participantsNCT07274813
What this trial is testing

A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid Tumors

Who this might be right for
Advanced/Metastatic Solid TumorsNSCLC
Shanghai Henlius Biotech 254
Testing effectiveness (Phase 2)Looking for participantsNCT05972135
What this trial is testing

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

Who this might be right for
Multiple Myeloma
SCRI Development Innovations, LLC 100
Testing effectiveness (Phase 2)Looking for participantsNCT07299747
What this trial is testing

Clinical Trial of VBC103 in Patients With Advanced Malignant Solid Tumors

Who this might be right for
Participants With Advanced Solid Tumor Malignancies
VelaVigo Bio Inc 255
Testing effectiveness (Phase 2)Looking for participantsNCT04930432
What this trial is testing

Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors

Who this might be right for
Solid TumorNon-Small Cell Lung CancerHead and Neck Cancer+1 more
Betta Pharmaceuticals Co., Ltd. 400
Testing effectiveness (Phase 2)Active Not RecruitingNCT05410418
What this trial is testing

Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma

Who this might be right for
Lymphoma, FollicularFollicular Lymphoma
Washington University School of Medicine 34
Not applicableLooking for participantsNCT05106387
What this trial is testing

An Observational Extension Study for Adult Patients Treated in Study R5459-RT-1944 Who Receive a Kidney Transplant

Who this might be right for
Chronic Kidney Disease (CKD)
Regeneron Pharmaceuticals 20
Testing effectiveness (Phase 2)Looking for participantsNCT05125016
What this trial is testing

A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With Cemiplimab or REGN5678 for Adult Participants With Advanced Prostate Cancer

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Regeneron Pharmaceuticals 370
Testing effectiveness (Phase 2)Looking for participantsNCT04777084
What this trial is testing

The Efficacy and Safety of the Bispecific Anti-PD-1/PD-L1 Antibody IBI318 Combined with Lenvatinib in NSCLC.

Who this might be right for
Non-Small Cell Lung Cancer
Hunan Province Tumor Hospital 120
Load More Results